INTRODUCTION
Liver resection is a curative treatment for management of solitary liver cancer; however, tumor recurrence after curative surgery has limited treatment options. Tumor size, intrahepatic metastasis, microvascular invasion, serum AFP, and serum proteins induced by vitamin K antagonistII (PIVKAII), CRP, and serum alkaline phosphatase have been reported as risk factors associated with early recurrence [14] .
The most commonly used method for evaluating oncologic patients is F18fluoro2deoxyglucose positron emission tomography (18FFDG PET), which is based on glucose metabolism processes that are enhanced in rapidly growing cells and thus cause increased 18FFDG uptake [5] . PETCT is increasingly being used in the field of oncology not only for detecting and staging malignant tumors but also for monitoring therapy response and differentiating malignant from benign lesions [57] . PETCT has been used as a predictor of outcomes in various cancers. In addition, PETCT has been applied for the detection and evaluation of hepatocellular carcinoma (HCC).
PETCT is useful for evaluating patients with unexplained increased AFP after locoregional therapy for HCC and in differentiating malignant and benign portal vein thrombosis [8, 9] . However, PETCT is not currently included as an HCC diagnostic method because of its suboptimal sensitivity (<50%) for detection of new HCC. In a series of patients who underwent liver resection for HCC, preoperative positive PETCT imaging results were associated with poor tumor differentiation and appeared to predict poor outcomes such as tumor recurrence and death [10] . However, there are few studies on the prognostic value of 18FFDG PETCT in patients with HBVrelated HCC.
The purpose of the present study was to compare the out comes between PETpositive and PETnegative groups with HBVrelated HCC who underwent curative hepatic resection and to assess the prognostic value of positive PETCT for HCC recurrence and death.
METHODS

Patients
This study included patients who underwent surgical resection of solitary HCC based on preoperative radiological images between July 2007 and September 2014. This study was approved by the Institutional Review Board of Samsung Medical Center (SMC201608161001). A total of 226 patients with HBV related HCC underwent curative liver resection in our hospital. HCC was proved based on pathology after hepatectomy.
Exclusion criteria were as follows: mixed HCC and cholangio carcinoma on pathology; age <18 years; history of liver resection, transarterial chemoembolization, radiofrequency ablation (RFA), or percutaneous ethanol injection; history of radiation; concurrent intraoperative RFA; fibrolamellar HCC; lack of PET CT evaluation in the preoperative period; or loss to followup after hepatectomy. Demographic, preoperative laboratory, and pathologic data collected from electronic medical records were retrospectively reviewed.
None of the patients received postoperative adjuvant therapy before recurrence. All patients received antiviral therapy after liver resection. The procedures used for surveillance after liver resection have been described previously [1] .
Surgery and pathology
Surgical and pathological procedures used after liver resec tion have been described previously [4, 11] . Major hepatectomy was defined as resection of 3 or more segments, and minor hepatectomy was defined as resection of fewer than 3 seg ments. Postoperative histological assessment included maxi mum tumor size, encapsulation, intrahepatic metastasis, multi centric occurrence, microvascular invasion, serosal involvement, and cirrhosis. Intrahepatic metastasis and multicentric occu rrence were defined based on guidelines from the Liver Cancer Study Group of Japan [12] . The histologic grade of HCC was assigned according to the EdmonsonSteiner system as well dif ferentiated (grade I), moderately differentiated (grade II), or poorly differentiated (grades III, IV) [13] .
FDG PET-CT procedures
The PDF PETCT procedure in our hospital was previously described [14] . All FDG PETCT imaging was performed with dedicated PETCT scanners (Discovery STE, GE Healthcare, Milwaukee, WI, USA) at Samsung Medical Center. All patients fasted for at least 6 hours prior to intravenous administration of FDG. A blood glucose level ≤140 mg/dL was required before administering FDG. Approximately 5.5 MBq/kg of FDG was administered intra venously for the Discovery STE. Foci of increased metabolic acti vity were compared between normal surrounding tissues and tumor tissue and visually interpreted using a 2point grading score of (1) positive and (2) negative.
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, USA). Continuous variables are described as median with range. Categorical variables are expressed as number and percentage of patients. Fisher exact test was conducted to evaluate differences in the frequencies of categorical variables between the groups. Mann Whitney U analysis was conducted to evaluate differences in continuous variables between the two groups. Binary logistic regression analysis using significant factors (P < 0.1) was used to predict positive PETCT in the preoperative period. The KaplanMeier survival method was performed to evaluate dif ferences in patient survival between the 2 groups. Cox regre ssion analysis was performed to identify prognostic factors of patient survival. All tests were 2sided, and statistical signifi cance was defined as P < 0.05.
RESULTS
Baseline characteristics
The baseline characteristics of the PETnegative and PET positive groups are summarized in Table 1 . The median HBsAg titer was 4,435 cutoff index (COI) (range, 1-9,758 COI) in the PETpositive group and 3,319 COI (range, 1-20,093 COI) in the PETnegative group (P = 0.009). There were no statistically significant differences in sex, age, white blood cells, lympho cyte to neutrophil ratio, monocyte to neutrophil ratio, hemo globin level, platelet count, liver function tests, HBV DNA level, presence of HBeAg, or indocyanine green value between the 2 groups. The median AFP and PIVKAII levels were 14.1 ng/dL (range, 1.3-50,488.1 ng/dL) and 48 mAU/mL (range, 8-41,631 mAU/mL), respectively, in the PETnegative group compared with 18.3 ng/dL (range, 1.3-200,000 ng/mL) and 56 mAU/mL (range, 12-67,612 mAU/mL) in the PETpositive group. AFP and PIVKAII levels were not significantly different between the groups.
Perioperative and pathologic characteristics
The incidence of laparoscopic resection and major liver resection was not significantly different between PETpositive and PETnegative groups. Median tumor size was 3.3 cm (range, 1.0-16.5) in the PETpositive group and 2.8 cm (range, 0.3-16.0) in the PETnegative group (P = 0.036). There were no statistically significant differences in tumor grade, necrosis, encapsulation, microvascular invasion, portal vein tumor throm bosis, serosal involvement, intrahepatic metastasis, multi centric occurrence, or cirrhosis between the 2 groups. The incidence of bile duct tumor thrombi was 6.5% in the PETnegative group and 0.8% in the PETpositive group (P = 0.020). Tumor size > 3.5 cm (odds ratio [OR], 2.291; 95% confidence interval [CI], 1.130-4.645; P = 0.0022) and HBsAg titer > 1,000 COI (OR, 4.354; 95% CI, 1.932-9.813; P < 0.001) were predisposing factors of positive PETCT in multivariate analysis (Table 2) .
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HCC recurrence
The median followup duration was 42.5 months (range, 7-103 months) in the PETnegative group and 36.4 months (range, 5-70 months) in the PETpositive group (P = 0.008). The disease free survival rate at 1, 3, and 5 years was 76.3%, 64.4% and 60.3% in the PETnegative group, respectively, and 70.7%, 62.2%, and 58.9% in the PETpositive group (Fig. 1) (P = 0.547). The most common site of recurrence for both groups was an intrahepatic site (82.4% in the PETnegative group compared with 78.4% in the PETpositive group; P = 0.904). Multivariate analysis showed that serosal involvement and intrahepatic metastasis were closely associated with HCC recurrence (Table 2) .
Patient survival
The overall survival rate at 1, 3, and 5 years was 96.8%, 91.1%, and 85.1% in the PETnegative group, respectively, and 98.5%, 97.0%, and 97.0% in the PETpositive group (Fig. 2) . The overall survival curve for the PETpositive group was higher than that for the PETnegative group (P = 0.046). Multivariate analysis showed that tumor size > 3.5 cm and positive preoperative PET CT were closely associated with patient survival (Table 3) .
DISCUSSION
FDG PETCT is not used in the early evaluation of HCC pa tients because of high costs and low sensitivity. As metabolic acti vity in tumor cells can be higher than that in normal hepa to cytes, PETCT can be used for malignant characterization of tumors by assessing metabolic activity. Many studies have suggested that a positive FDG PETCT finding is a powerful predictor of prognosis in HCC patients [5, 15, 16] . One of the major goals in the surgical treatment of HCC is minimizing the risk of tumor recurrence, which is strongly associated with patient survival.
However, the present study failed to prove a correlation between PET results and patient outcomes after liver resection. Our data showed that baseline, perioperative, and pathologic characteristics in the PETnegative group were not different 
Annals of Surgical Treatment and Research 187
from those in the PETpositive group with the exception of HBsAg titer, tumor size, and the presence of bile duct tumor thrombi. The diseasefree survival rates for the PETpositive group were not significantly different from those in the PET negative group; however, the overall patient survival rates in the PETpositive group were better than those in the PETnegative group (P = 0.046). In addition, multivariate analysis showed that negative PETCT finding was an important predictor of poor patient survival. A previous study showed that PETpositive HCC was signifi cantly associated with AFP >200 ng/mL and microvascular invasion [17] . Another study reported that preoperative 18FFDG uptake was closely associated with metabolic activity and tumor grade. Therefore, there was a difference in uptake of 18FFDG according to degree of tumor differentiation of HCC [18] ; the uptake of 18FFDG in well and welltomoderately differentiated HCC was similar to that in normal liver, whereas moderatetopoorly and poorly differentiated HCC demonstrated increased uptake [19] . However, our results did not confirm this.
The present study revealed that positive PET CT was closely associated with tumor size >3.5 cm and HBsAg titer > 1,000 COI in patients with HBVrelated HCC who underwent curative hepatectomy. It has been reported that quantification of HBsAg is associated with the level of intrahepatic covalently closed circular DNA (cccDNA), which reflects the number of HBV infected hepatocytes [20] . Intrahepatic cccDNA level in the tumor tissue was higher than that in the nontumor tissue of HBsAgpositive patients with HCC [21] . Our results suggest that a positive PETCT findings reflected cccDNA level based on the relationship between positive PETCT finding and high HBsAg titer.
A previous study reported a correlation between PETCT findings and prognosis in HCC patients [22] . Another study showed a good correlation among 18FFDG uptake, tumor volume doubling time, and prognosis [16] . Many studies reported similar results and strengthened the correlation bet ween 18FFDG uptake and HCC prognosis regardless of tumor stage or treatment strategy [5, 6, 15, 16, 23] . However, the present study did not find similar outcomes in hepatectomy patients. HCC recurrence was not different between PETpositive and PETnegative groups, and patient survival was better for the PETpositive group compared with the PETnegative group. Tumor recurrences in most gastrointestinal cancers involve not only local recurrence, but also remote metastases. Most cases of recurrent HCC after hepatectomy in patients with HBVrelated HCC involved development of intrahepatic metastasis or de novo recurrence. Since tumor recurrence patterns are different between HCC and other gastrointestinal cancers, PETCT does not seem to predict the exact prognosis after curative surgical resection in HCC patients.
Underestimation of 18FFDG uptake by malignant lesions that contributes to PET falsenegative findings can occur because of physiological movements of the liver during emission scans [16] . The degree of this underestimation is variable, particularly in the case of subcentimeter lesions, and might even lead to nonvisualization of the lesion [24] . However, no information is available in the literature on prognosis after liver resection, during which PET can give falsenegative results.
In 2 studies, PETCT in liver transplantation patients predicted HCC recurrence [17, 25] . However, those studies in cluded many patients with various etiologies who received several locoregional therapies. The present study focused on pa tients with solitary HBVrelated HCC with preoperative loco regional therapies who underwent curative hepatic resection. PETCT scans in patients undergoing liver transplant or hepa tectomy as treatment for HCC are considered to have different value in terms of tumor biology worsening during multiple loco regional therapies [26] .
Jong Man Kim, et al: Preoperative PET uptake in hepatectomy This study has several limitations. First, the study is retro spective. Second, selection bias can occur due to the inclusion of hepatectomy patients with preoperative radiologically solitary tumor and wellpreserved liver function. Third, we did not measure standardized uptake value (SUV) in the tumor and nontumor lesions. SUV in the liver, including normal liver and tumor, was heterogeneous and therefore dependent on the arbitrary selected points. In addition, the SUV ratio varies according to the examiner. We compared PET CTpositive and PET CTnegative groups because positive and negative findings in the PET CT were clearly seen. Fourth, intrahepatic cccDNA level in the resected liver specimen was not measured; therefore, we could not demonstrate the relationship between serum HBsAg level and intrahepatic cccDNA level in HBVrelated HCC. In addition, regular assessment of HBsAg level was not performed during the followup after resection. Consequently, the correlation between HBsAg level and PETCT findings was not investigated when HCC recurrence was detected in patients undergoing resection.
In conclusion, the present study showed that large tumor size and increased HBsAg titer are associated with positive PET CT findings in patients with HBVrelated HCC. Preoperative 18FFDG PET CT is not an independent prognostic factor for survival in these patients undergoing curative treatment; however, positive PETCT appears to be associated with better patient survival. These results suggest that 18FFDG PETCT scans do not have a dominant predictive role in HCC recurrence of HBVrelated HCC patients. Our study emphasizes that further prospective studies are needed in order to assess the potential prognostic role of 18FFDG PETCT in patients undergoing hepatectomy.
